Detalhe da pesquisa
1.
Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.
Respir Res
; 23(1): 202, 2022 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35945604
2.
Protein citrullination and NET formation do not contribute to the pathology of A20/TNFAIP3 mutant mice.
Sci Rep
; 13(1): 17992, 2023 10 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37865713
3.
A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19.
Sci Transl Med
; 15(710): eadi0252, 2023 08 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37611083
4.
Loss of GM-CSF-dependent instruction of alveolar macrophages in COVID-19 provides a rationale for inhaled GM-CSF treatment.
Cell Rep Med
; 3(12): 100833, 2022 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36459994
5.
TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C.
J Exp Med
; 219(2)2022 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914824
6.
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Lancet Respir Med
; 9(12): 1427-1438, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34756178
7.
Case Report: Convalescent Plasma, a Targeted Therapy for Patients with CVID and Severe COVID-19.
Front Immunol
; 11: 596761, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33329586